Page last updated: 2024-12-07
chrysobactin
Description
chrysobactin: from Erwinia chrysanthemi; has siderophore activity; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
chrysobactin : A catechol-type siderophore with a structure of D-lysyl-L-serine substituted on N(2) of the lysyl residue by a 2,3-dihydroxybenzoyl group. It is produced by the Gram-negative bacillus Dickeya dadantii (previously known as Erwinia chrysanthem). Only the catecholate hydroxyl groups participate in metal coordination, so chrysobactin cannot provide full 1:1 coordination of Fe(III); at neutral pH and concentrations of about 0.1 mM, ferric chrysobactin exists as a mixture of bis and tris complexes. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 129039 |
| CHEBI ID | 61345 |
| MeSH ID | M0163219 |
Synonyms (12)
| Synonym |
|---|
| chrysobactin |
| n(2)-(2,3-dihydroxybenzoyl)-d-lysyl-l-serine |
| 120124-51-8 |
| CHEBI:61345 |
| 2-(2,3-dihydroxybenzoyl)-d-lysyl-l-serine |
| (2s)-2-[[(2r)-6-amino-2-[(2,3-dihydroxybenzoyl)amino]hexanoyl]amino]-3-hydroxypropanoic acid |
| n-(n(2)-(2,3-dihydroxybenzoyl)lysyl)serine |
| l-serine, n-(n2-(2,3-dihydroxybenzoyl)-d-lysyl)- |
| DTXSID10152685 |
| Q27131049 |
| (2,3-dihydroxybenzoyl)-d-lysyl-l-serine |
| AKOS040751166 |
Research Excerpts
Overview
Chrysobactin is a catechol-type siderophore and, as we have previously observed with the entA locus of Escherichia coli, the E. coli bacterium.
| Excerpt | Reference | Relevance |
|---|
| "Trichrysobactin is a cyclic trimer of chrysobactin joined by a triserine lactone backbone." | ( Chrysobactin siderophores produced by Dickeya chrysanthemi EC16.
Butler, A; Sandy, M, 2011) | 2.33 |
| "Chrysobactin is a catechol-type siderophore and, as we have previously observed with the entA locus of Escherichia coli, the E." | ( Genetic analysis of the Erwinia chrysanthemi 3937 chrysobactin iron-transport system: characterization of a gene cluster involved in uptake and biosynthetic pathways.
Enard, C; Expert, D; Franza, T; van Gijsegem, F, 1991) | 1.26 |
Roles (2)
| Role | Description |
|---|
| siderophore | Any of low-molecular-mass iron(III)-chelating compounds produced by microorganisms for the purpose of the transport and sequestration of iron. |
| bacterial metabolite | Any prokaryotic metabolite produced during a metabolic reaction in bacteria. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (5)
| Class | Description |
|---|
| catechols | Any compound containing an o-diphenol component. |
| dipeptide | Any molecule that contains two amino-acid residues connected by peptide linkages. |
| monocarboxylic acid | An oxoacid containing a single carboxy group. |
| primary alcohol | A primary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has either three hydrogen atoms attached to it or only one other carbon atom and two hydrogen atoms attached to it. |
| primary amino compound | A compound formally derived from ammonia by replacing one hydrogen atom by an organyl group. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (17)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 1 (5.88) | 18.7374 |
| 1990's | 8 (47.06) | 18.2507 |
| 2000's | 7 (41.18) | 29.6817 |
| 2010's | 1 (5.88) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.35
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 12.35 (24.57) | | Research Supply Index | 2.89 (2.92) | | Research Growth Index | 5.24 (4.65) | | Search Engine Demand Index | 0.00 (26.88) | | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 17 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |